🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Shalby Limited SHALBY NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.shalby.org
Company Profile ↓
₹168.60
-8.92% 1Y
Mkt Cap₹1,821.04 Cr
P/E52.20
P/B1.81
52W High₹266.83
52W Low₹126.80
Book Value₹93.07
EPS (TTM)₹3.23

Company Overview

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 12.6% CAGR over the past five years.

Recent Developments

  • Mar 2026 Revenue of ₹1,141.43 Cr (+5.0% YoY); net profit ₹37.39 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +5.0%, earnings +500.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 12.6%, profit CAGR -18.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:12.60%
1 Year:5.01%

Compounded Profit Growth

5 Years:-17.96%
1 Year:500.90%

Stock Price Performance

1 Year:-8.92%
6 Months:-7.84%
3 Months:+5.60%
1 Month:-1.18%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 30% of range
₹126.80 ₹266.83
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)46.07 · Neutral
Price Performance
1M-1.18%
3M+5.60%
6M-7.84%
1Y-8.92%
Valuation vs Sector

P/E of 52.20 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 12.6% over 5 years.

CONS

  • Trading at a high P/E of 52.2.
  • Earnings shrank at -18.0% CAGR over 5 years.
  • Trading 36.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
52.20
Industry PE
39.97
Forward P/E
17.94
PEG Ratio
-
Book Value
₹93.07
Price to Book
1.81
P/S
1.61
EV/EBITDA
16.32
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
12.60%
Profit 5Y
-17.96%
Revenue (YoY)
5.01%
Earnings (YoY)
500.90%

Profitability & Returns

ROCE
7.88%
ROE
3.72%
ROA
2.03%
Profit Margin
3.28%
Op Margin
6.37%
Gross Margin
40.87%
EPS (Latest Qtr)
₹1.72
EPS (TTM)
₹3.23

Balance Sheet & Liquidity

Debt/Equity
0.59
Quick Ratio
0.60
Current Ratio
1.25
Debt
₹594.59 Cr
Total Assets
₹1,839.13 Cr
Current Assets
₹719.33 Cr
Working Capital
₹143.64 Cr

Ownership

Promoter Holding
76.47%
Chg in Prom Hold
2.14%
FII / Inst Holding
0.05%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹1,821.04 Cr
Total Revenue (TTM)
₹1,141.43 Cr
EBITDA
₹169.54 Cr
Free Cash Flow
₹-149.06 Cr
Operating Cash Flow
₹-1.10 L
Shares Outstanding
₹10.80 Cr
Gross Margin
40.87%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SHALBY Shalby Limited NSEPHARMA 168.60 52.20 ₹1,821.04 Cr 0.00% 7.88% 3.72% 12.60% -17.96%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 199.00 Cr235.00 Cr238.00 Cr216.00 Cr244.00 Cr279.00 Cr268.00 Cr276.00 Cr264.89 Cr296.43 Cr285.43 Cr272.13 Cr287.44 Cr
Cost of Revenue --------165.57 Cr178.86 Cr163.76 Cr160.25 Cr172.02 Cr
Gross Profit --------99.32 Cr117.56 Cr121.67 Cr111.88 Cr115.42 Cr
Operating Expenses 173.00 Cr192.00 Cr185.00 Cr174.00 Cr205.00 Cr234.00 Cr235.00 Cr242.00 Cr94.71 Cr92.55 Cr97.43 Cr99.24 Cr104.56 Cr
Operating Income 13.00 Cr31.00 Cr41.00 Cr30.00 Cr23.00 Cr29.00 Cr16.00 Cr18.00 Cr4.61 Cr25.02 Cr24.24 Cr12.64 Cr10.86 Cr
EBITDA 26.00 Cr43.00 Cr53.00 Cr42.00 Cr39.00 Cr45.00 Cr33.00 Cr34.00 Cr26.16 Cr48.55 Cr46.09 Cr37.48 Cr37.43 Cr
Interest Expense 3.00 Cr3.00 Cr3.00 Cr4.00 Cr6.00 Cr8.00 Cr9.00 Cr11.00 Cr10.67 Cr9.37 Cr9.64 Cr10.64 Cr9.34 Cr
Pretax Income 19.00 Cr33.00 Cr43.00 Cr31.00 Cr22.00 Cr30.00 Cr14.00 Cr12.00 Cr-73.90 L22.65 Cr19.07 Cr9.23 Cr9.61 Cr
Tax Provision 5.32 Cr12.21 Cr15.05 Cr11.78 Cr5.72 Cr15.60 Cr11.62 Cr14.88 Cr11.45 Cr14.97 Cr11.80 Cr7.95 Cr-8.85 Cr
Net Income 14.00 Cr21.00 Cr28.00 Cr19.00 Cr16.00 Cr15.00 Cr2.00 Cr-3.00 Cr-11.02 Cr8.92 Cr8.38 Cr1.76 Cr18.32 Cr
Diluted EPS 1.291.932.551.771.541.450.31-0.17-1.130.710.680.121.72

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 275.00 Cr290.00 Cr324.00 Cr378.00 Cr462.00 Cr487.00 Cr431.00 Cr-799.63 Cr928.22 Cr1,086.95 Cr1,141.43 Cr
Cost of Revenue --------435.11 Cr505.18 Cr634.97 Cr674.89 Cr
Gross Profit --------364.52 Cr423.04 Cr451.99 Cr466.54 Cr
Operating Expenses 207.00 Cr235.00 Cr252.00 Cr299.00 Cr379.00 Cr404.00 Cr342.00 Cr-270.75 Cr294.70 Cr385.14 Cr393.77 Cr
Operating Income 47.00 Cr45.00 Cr54.00 Cr56.00 Cr50.00 Cr47.00 Cr52.00 Cr-93.77 Cr128.34 Cr66.85 Cr72.77 Cr
EBITDA 68.00 Cr56.00 Cr71.00 Cr79.00 Cr83.00 Cr83.00 Cr89.00 Cr-158.10 Cr194.83 Cr160.20 Cr169.54 Cr
Interest Expense 5.00 Cr10.00 Cr11.00 Cr12.00 Cr9.00 Cr7.00 Cr5.00 Cr-7.97 Cr14.40 Cr38.71 Cr38.99 Cr
Pretax Income 43.00 Cr36.00 Cr50.00 Cr54.00 Cr50.00 Cr57.00 Cr55.00 Cr-102.04 Cr128.19 Cr55.73 Cr60.56 Cr
Tax Provision 18.49 Cr-36.00 L21.50 Cr14.58 Cr18.50 Cr29.07 Cr12.65 Cr-34.37 Cr44.69 Cr53.81 Cr25.88 Cr
Net Income 25.00 Cr36.00 Cr29.00 Cr39.00 Cr32.00 Cr28.00 Cr42.00 Cr-67.70 Cr84.08 Cr6.22 Cr37.39 Cr
Diluted EPS 7.364.303.403.652.932.553.93-6.307.830.183.23

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 351.00 Cr504.00 Cr679.00 Cr961.00 Cr939.00 Cr967.00 Cr997.00 Cr-1,281.36 Cr1,607.53 Cr1,703.65 Cr1,839.13 Cr
Current Assets --------517.25 Cr552.25 Cr657.96 Cr719.33 Cr
Cash & Equivalents --------12.24 Cr27.18 Cr34.78 Cr21.90 Cr
Inventory --------185.40 Cr235.20 Cr319.21 Cr376.38 Cr
Receivables --------106.36 Cr144.63 Cr175.21 Cr228.42 Cr
Total Liabilities --------353.75 Cr599.75 Cr708.33 Cr833.44 Cr
Current Liabilities --------194.38 Cr323.27 Cr455.32 Cr575.69 Cr
Long Term Debt --------67.42 Cr175.97 Cr136.67 Cr152.88 Cr
Total Debt 98.00 Cr224.00 Cr328.00 Cr114.00 Cr71.00 Cr62.00 Cr44.00 Cr-180.50 Cr377.87 Cr475.93 Cr594.59 Cr
Total Equity 168.00 Cr204.00 Cr251.00 Cr751.00 Cr780.00 Cr799.00 Cr835.00 Cr-927.68 Cr1,000.37 Cr992.19 Cr1,005.23 Cr
Shares Outstanding --------10.80 Cr10.80 Cr10.80 Cr10.80 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --60.00 Cr14.00 Cr43.00 Cr55.00 Cr79.00 Cr-67.78 Cr19.60 Cr-4.34 Cr-1.10 L
Investing Cash Flow ---153.00 Cr-236.00 Cr1.00 Cr-31.00 Cr-51.00 Cr--61.08 Cr38.07 Cr-35.64 Cr-97.28 Cr
Financing Cash Flow --96.00 Cr222.00 Cr-51.00 Cr-22.00 Cr-30.00 Cr--50.02 Cr-150.69 Cr47.58 Cr84.41 Cr
Capital Expenditure ---158.00 Cr-138.00 Cr-31.00 Cr189.00 Cr-21.00 Cr--18.48 Cr-47.11 Cr-71.45 Cr-149.04 Cr
Free Cash Flow ---98.00 Cr-124.00 Cr12.00 Cr244.00 Cr58.00 Cr-49.29 Cr-27.51 Cr-75.79 Cr-149.06 Cr
Net Change in Cash --3.00 Cr0-6.00 Cr3.00 Cr-2.00 Cr--43.33 Cr-93.02 Cr7.60 Cr-12.88 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------45.6%45.6%41.6%40.9%
Operating Margin % 17.1%15.5%16.7%14.8%10.8%9.7%12.1%-11.7%13.8%6.1%6.4%
Net Margin % 9.1%12.4%9.0%10.3%6.9%5.7%9.7%-8.5%9.1%0.6%3.3%
ROE % 14.9%17.6%11.6%5.2%4.1%3.5%5.0%-7.3%8.4%0.6%3.7%
ROCE % --------8.6%10.0%5.4%5.8%

Shareholding Pattern

Insiders
76.47%
Institutions
0.05%
Public Float
0.23%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SHALBY

Google News Mon, 22 Sep 2025

Smallcap hospital stock zooms 14% in weak market after promoter hikes stake - Business Standard

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOYUVTbDZzN3dESFhMeGttUFc1bU03VXVVd0ZLWTdYWC1sc29IUkV2NjkwbWpXbU9NSmJKWDBEaFlxNUZPUVFsYjd5aS0wWFo5YmxiSUhDVGh4SGVmRGpEV0lTMXVwakZvRHhGWElHc1JSdFJaZXVtQ3NnY1Q0ZENZZnI5U2Y4b2Q0ZFdVZk…

Google News Wed, 27 May 2026

Shalby Limited Schedules Board Meeting on May 27, 2026 to Approve Q4FY26 Financial Results - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNc2NuMlVZOTRfTHdiMU5TTHRwUWlWYVJwemlDY2VUSE05WnRlazdvRWRieS1feUxHYmF2aTRwc095ejg2aXJQenZEa25fZnNPZ241ZXF3MWhXQ1BQLWdXZ0l1N0Z0VlpNM2hFdm1PYjNmTktxRFY3aXNVaUxGT19lZE96VDNZSlp4M0hueG…

Google News Fri, 20 Feb 2026

5 Smallcap Hospital Stocks to Add to Your Watchlist - Equitymaster

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQbE5EZjZ4X2VYZ05GWW5tQWF0YTV6Rm9mdG9iN3JEd3FzMTE2NWRZV2FEZnhCalJ6RXk4dFVDN1Y0ZEtKay1CQmJDaFRQWC1rQkFPTTk3X1BadGkzWXBkRk1wWVZ3dGxfdjJ4N3FoR09XQ3o0OGM1bVVhX01GUW1fY3BqU05MeTZmM2FMMD…

Google News Sat, 03 Jan 2026

Shalby Ltd. Share Price Today - Shalby Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE1OQjdzd1Bqa0pwSkw5azVsWllCSHBsYXpEbzRqRWs4TGRXWE4zRlpKQVJIU1B2cFgyUDdMTUdPZkl5S2djblNpeC1VQm5raFU1RUZkUmZmQW90eUhyWUpSajZ4Z3FFVzB2U1ZSRGtFYWUtZXRmRUE?oc=5" target="_blank">Shalby L…

Google News Mon, 13 Apr 2026

Two dozen stocks including, L&T, NTPC, HUDCO, NBCC, Zaggle, AstraZeneca, Apollo Hospitals, Shalby, TGV Sraac will be in focus today - BusinessLine

<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxPbFJ1cGxDVlktdExxNlhXcnlZaEdqV2ZfM3JyMDRDY2dNS3ZZY1NkbVQxd3hTZjBOdzFVMDBiM1ZmSlR0TjVTd3JTYWtBRVBMS09OVHJGVWVxZEhuU1Jac1VJLVVSTUpTaTdJR2xtWEpDRnMtRC1ySnVWNDdJMVAyRGJJSzh2NkRQY3RNYz…

Google News Mon, 29 Jun 2026

Shalby disposes of arbitration proceedings against two doctors - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNV280UE5Qb3FSNjRveVdqb18tbnc2c1ZuSk4wZ1AxLXlITlFfOGlNVUV1cVFReEN3QUpMTldNVXY4VkZwV1Z6dlpfWk1Sc3plbllhTjRjUDJ3VFhmZm1UXzY3aC1ha2JaNDNENnM0bUhNdmxEXy1wYzdnLVQ5eWEyeXFVVk8xMWwwb29sYm…

SHALBY — Frequently Asked Questions

What is the current share price of Shalby Limited (SHALBY)?

As of 2026-07-15 09:52 IST, Shalby Limited (SHALBY) trades at ₹168.60 on NSE. Its 52-week range is ₹126.80 to ₹266.83.

What is the market capitalisation of SHALBY?

Shalby Limited (SHALBY) has a market capitalisation of ₹1,821.04 Cr on NSE.

What is the P/E ratio of SHALBY?

SHALBY trades at a trailing price-to-earnings (P/E) ratio of 52.20. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.81.

What is the return on equity (ROE) of SHALBY?

SHALBY has a return on equity (ROE) of 3.72%. Its return on capital employed (ROCE) is 7.88%.

Is SHALBY a good stock to buy?

This page provides a data-driven analysis of Shalby Limited (SHALBY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space